Expression and role of regulator of G-protein signaling 5 in squamous cell carcinoma of the tongue.


Journal

Clinical and experimental dental research
ISSN: 2057-4347
Titre abrégé: Clin Exp Dent Res
Pays: United States
ID NLM: 101692332

Informations de publication

Date de publication:
04 2019
Historique:
received: 26 10 2018
revised: 03 12 2018
accepted: 04 12 2018
entrez: 4 5 2019
pubmed: 3 5 2019
medline: 3 5 2019
Statut: epublish

Résumé

Regulator of G-protein signaling (RGS) 5 acts as a GTPase-activating protein to negatively regulate G-protein signaling. RGS5 is reportedly related to the invasion and metastasis of cancers, such as nonsmall lung cancer and hepatocellular carcinoma. We examined RGS5 expression and its relationship with invasion in squamous cell carcinoma (SCC) of the tongue. For immunohistochemical analysis of RGS5, we used SCC tissues of the tongue obtained from 43 patients. We examined the relationship between RGS5 expression in the deepest point of invasion and clinicopathological features. Because the invasion and metastasis of cancers are related to epithelial-mesenchymal transition (EMT), we carried out staining for N-cadherin, vimentin, and E-cadherin to examine the relationship between EMT and RGS5. RGS5 expression in the deepest point of invasion in SCC of the tongue was observed in 32 cases (75%). Immunohistochemical analysis revealed a significant correlation between RGS5 expression in the aggressive invasion pattern, invasion depth, and lymphovascular invasion. Kaplan-Meier analysis revealed that high RGS5 expression was associated with postoperative early lymph node metastasis. Further, a significant positive correlation was observed between RGS5 and N-cadherin (

Identifiants

pubmed: 31049219
doi: 10.1002/cre2.166
pii: CRE2166
pmc: PMC6483038
doi:

Substances chimiques

Antigens, CD 0
CDH1 protein, human 0
CDH2 protein, human 0
Cadherins 0
RGS Proteins 0
RGS5 protein, human 0
VIM protein, human 0
Vimentin 0

Types de publication

Journal Article

Langues

eng

Pagination

160-169

Déclaration de conflit d'intérêts

The authors have no conflict of interest.

Références

Cancer Biol Med. 2012 Dec;9(4):234-41
pubmed: 23691483
Oral Oncol. 2009 Apr-May;45(4-5):309-16
pubmed: 18804401
Periodontol 2000. 2011 Oct;57(1):51-72
pubmed: 21781179
J Cancer Res Ther. 2018 Jan-Mar;14(2):382-387
pubmed: 29516924
Histopathology. 2010 Aug;57(2):295-303
pubmed: 20659175
Clin Exp Dent Res. 2019 Mar 04;5(2):160-169
pubmed: 31049219
Oncol Lett. 2018 Feb;15(2):1763-1770
pubmed: 29434872
World J Gastroenterol. 2010 Nov 28;16(44):5642-6
pubmed: 21105200
Virchows Arch. 2015 Jul;467(1):39-46
pubmed: 25838076
Biochem Pharmacol. 2009 Nov 15;78(10):1289-97
pubmed: 19559677
J Surg Oncol. 2013 Sep;108(3):192-6
pubmed: 23868206
J Surg Oncol. 2012 Mar 15;105(4):420-4
pubmed: 21780128
Br J Cancer. 2003 Aug 4;89(3):557-63
pubmed: 12888830
Head Neck Pathol. 2013 Sep;7(3):211-23
pubmed: 23250819
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Oral Oncol. 2006 Mar;42(3):229-39
pubmed: 16150633
Am J Surg Pathol. 2005 Feb;29(2):167-78
pubmed: 15644773

Auteurs

Yushi Abe (Y)

Department of Pathology Kurume University School of Medicine Kurume Japan.
Dental and Oral Medical Center Kurume University School of Medicine Kurume Japan.

Sachiko Ogasawara (S)

Department of Pathology Kurume University School of Medicine Kurume Japan.

Jun Akiba (J)

Department of Diagnostic Pathology Kurume University Hospital Kurume Japan.

Yoshiki Naito (Y)

Department of Pathology Kurume University School of Medicine Kurume Japan.
Department of Diagnostic Pathology Kurume University Hospital Kurume Japan.

Reiichiro Kondo (R)

Department of Pathology Kurume University School of Medicine Kurume Japan.

Ken Nakamura (K)

Dental and Oral Medical Center Kurume University School of Medicine Kurume Japan.

Jingo Kusukawa (J)

Dental and Oral Medical Center Kurume University School of Medicine Kurume Japan.

Hirohisa Yano (H)

Department of Pathology Kurume University School of Medicine Kurume Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH